Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ACADIA Pharmaceuticals Inc., Nurix Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Latest Biotechnology and ACADIA Pharmaceuticals Inc., Nurix Therapeutics, Inc. Stock News

As of December 10, 2025, ACADIA Pharmaceuticals Inc. had a $4.5 billion market capitalization, compared to the Biotechnology median of $226.0 million. ACADIA Pharmaceuticals Inc.’s stock is up 45.9% in 2025, up 0.8% in the previous five trading days and up 55.15% in the past year.

Currently, ACADIA Pharmaceuticals Inc.’s price-earnings ratio is 17.4. ACADIA Pharmaceuticals Inc.’s trailing 12-month revenue is $1.0 billion with a 24.9% net profit margin. Year-over-year quarterly sales growth most recently was 11.3%. Analysts expect adjusted earnings to reach $0.815 per share for the current fiscal year. ACADIA Pharmaceuticals Inc. does not currently pay a dividend.

As of December 10, 2025, Nurix Therapeutics, Inc. had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. Nurix Therapeutics, Inc.’s stock is up 2.7% in 2025, up 7.4% in the previous five trading days and down 2.54% in the past year.

Currently, Nurix Therapeutics, Inc. does not have a price-earnings ratio. Nurix Therapeutics, Inc.’s trailing 12-month revenue is $83.7 million with a -292.5% net profit margin. Year-over-year quarterly sales growth most recently was -37.3%. Analysts expect adjusted earnings to reach $-3.099 per share for the current fiscal year. Nurix Therapeutics, Inc. does not currently pay a dividend.

How We Compare ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
ACADIA Pharmaceuticals Inc.	ACAD	D
Nurix Therapeutics, Inc.	NRIX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

ACADIA Pharmaceuticals Inc. has a Value Score of 24, which is Expensive. Nurix Therapeutics, Inc. has a Value Score of 7, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc., Nurix Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc., Nurix Therapeutics or Inc. is the better investment when it comes to value.

ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
ACADIA Pharmaceuticals Inc.	ACAD	D
Nurix Therapeutics, Inc.	NRIX	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

ACADIA Pharmaceuticals Inc. has a Growth Score of 32, which is Weak. Nurix Therapeutics, Inc. has a Growth Score of 29, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither ACADIA Pharmaceuticals Inc., Nurix Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ACADIA Pharmaceuticals Inc., Nurix Therapeutics or Inc. is the better investment when it comes to sustainable growth.

ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
ACADIA Pharmaceuticals Inc.	ACAD	B
Nurix Therapeutics, Inc.	NRIX	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

ACADIA Pharmaceuticals Inc. has a Momentum Score of 76, which is Strong. Nurix Therapeutics, Inc. has a Momentum Score of 93, which is Very Strong.

The Momentum Grade Winner: Nurix Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Nurix Therapeutics, Inc. is considered to have stronger momentum compared to ACADIA Pharmaceuticals Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Nurix Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc. Grades

In addition to Growth, Value and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ACADIA Pharmaceuticals Inc., Nurix Therapeutics or Inc. Stock?

Overall, ACADIA Pharmaceuticals Inc. stock has a Value Score of 24, Growth Score of 32 and Momentum Score of 76.

Nurix Therapeutics, Inc. stock has a Value Score of 7, Growth Score of 29 and Momentum Score of 93.

Comparing ACADIA Pharmaceuticals Inc., Nurix Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.